PI3K inhibition with PIQRAY has been shown to induce an increase in estrogen receptor (ER) transcription in breast cancer cells1
PIQRAY inhibits the alpha isoform of PI3K 50 times more potently than other PI3K isoforms (β, γ, δ)2
PIQRAY is a nonchemotherapeutic α-selective PI3K inhibitor that works synergistically with fulvestrant across both the PI3K and ER pathways, respectively1
Based on in vitro/in vivo studies. Preclinical activity does not necessarily correlate with clinical outcomes.
PI3Kα, α isoform of phosphatidylinositol-3-kinase.